CEA | Jotup

Edible Garden Schedules Fourth Quarter 2023 Financial Results and Business Update Conference Call

Retrieved on:

Monday, March 25, 2024

BELVIDERE, NJ, March 25, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, announced today that it will host a conference call on Monday April 1, 2024, at 8:00 AM Eastern Time to discuss financial results for the quarter and year ended December 31, 2023, and provide a business update.

Key Points:

BELVIDERE, NJ, March 25, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, announced today that it will host a conference call on Monday April 1, 2024, at 8:00 AM Eastern Time to discuss financial results for the quarter and year ended December 31, 2023, and provide a business update.
The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 297232.
A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2914/50246 or on the investor relations section of the company’s website, https://ediblegardenag.com/presentations/ .
A webcast replay will be available on the investor relations section of the Company’s website at https://ediblegardenag.com/presentations/ through April 1, 2025.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on:

Thursday, March 21, 2024

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points:

ET to discuss the financial results and provide a business update
SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Retrieved on:

Monday, March 18, 2024

Entrepreneurship, Capsule, Patient, Food and Drug Administration, Rosacea, NDA, Red, Minocycline, Erythema, Food, Marketing, FDA, CEA, Physician, IGA, PDUFA, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.

Key Points:

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.
The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.
DFD-29 demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea® 40 mg capsules, and placebo for Investigator’s Global Assessment (IGA) treatment success as well as the reduction in the total inflammatory lesion count in both studies.
For the secondary endpoint evaluating erythema (redness) associated with rosacea, DFD-29 showed a statistically significant reduction in Clinician’s Erythema Assessment (CEA) compared to placebo in both clinical trials.”

Edible Garden Announces Pulp Sustainable Gourmet Sauces Now Available Through KeHE Distributors, LLC

Retrieved on:

Thursday, March 14, 2024

Maker, Natural product, Target, Growth, EXPO, Kaph, Edible, National Organic Program, Whole Foods Market, CEA, Meal

BELVIDERE, NJ, March 14, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today announced at Natural Products EXPO WEST® 2024 that KeHE Distributors will carry Edible Garden’s new line of Pulp sustainable gourmet sauces and chili-based products.

Key Points:

BELVIDERE, NJ, March 14, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today announced at Natural Products EXPO WEST® 2024 that KeHE Distributors will carry Edible Garden’s new line of Pulp sustainable gourmet sauces and chili-based products.
Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, “At last year’s Natural Products EXPO WEST® 2023, KeHE Distributors selected Edible Garden as one of their top picks to visit.
The introduction of the Pulp line has been met with positive feedback from sauce lovers everywhere.
With KeHE's extensive national distribution network carrying the Pulp line, we are highly optimistic that this collaboration will significantly boost the growth and visibility of both the Pulp line and the Edible Garden brand."

Dome Construction Awarded Its 21st CEA Excellence in Safety and 8th President’s Awards

Retrieved on:

Tuesday, March 19, 2024

Commercial Building & Real Estate, Construction & Property, Building Systems, REIT, Construction, CEA, Pharmaceutical industry

Dome Construction , one of California’s leading general contractors, today announced it won two awards from the Construction Employers’ Association (CEA), the Excellence in Safety award for the 21st year in a row and the President’s Safety Award for the 5th year in a row, its 8th time overall.

Key Points:

Dome Construction , one of California’s leading general contractors, today announced it won two awards from the Construction Employers’ Association (CEA), the Excellence in Safety award for the 21st year in a row and the President’s Safety Award for the 5th year in a row, its 8th time overall.
The Excellence in Safety Award winners have achieved both a total incident rate and a lost workday incident rate 25 percent below the industry average, an experience modification rate below 1.0, a flat or negative experience modification trend over the past four years, and a demonstration of an active safety training program.
The President’s Safety Award recognizes CEA member firms whose safety programs exceed industry standards.
President’s Safety Award winners are recognized for having achieved both a total injury and incident rate and a lost workday rate at least 50 percent below the industry average, and an experience modification rate of .70 or less.

BITB Crosses $2 Billion in Assets, Generates Largest Inflows of Any Crypto Specialist1

Retrieved on:

Monday, March 11, 2024

Today, over 3,000 wealth teams, RIAs, family offices, and institutional clients trust Bitwise as their specialist partner in the crypto space.

Key Points:

Today, over 3,000 wealth teams, RIAs, family offices, and institutional clients trust Bitwise as their specialist partner in the crypto space.
Bitwise’s national team of crypto experts is available to meet with investment professionals any time and in person.
Bitwise’s product offerings include five other crypto-themed ETFs, the world’s largest crypto index fund, private placement funds, alpha solutions, and separately managed account (SMA) solutions.
As of March 8, 2024, Bitwise has experienced net inflows of $1.35 billion, Valkyrie has experienced net inflows of $264 million, and Grayscale has experienced net outflows of more than $10 billion.

Partner Therapeutics' Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Retrieved on:

Wednesday, April 3, 2024

LEXINGTON, Mass., April 3, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the inhaled use of Leukine (sargramostim), branded in Japan as Sargmalin, to treat aPAP. PTx licensed rights for certain indications in Japan to Nobelpharma in 2022. Leukine is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast. Leukine is not approved outside Japan for aPAP or as an inhalation therapy. Partner Therapeutics will manufacture Sargmalin for Nobelpharma at its manufacturing facility in Lynnwood, WA.

Key Points:

Leukine is not approved outside Japan for aPAP or as an inhalation therapy.
Partner Therapeutics will manufacture Sargmalin for Nobelpharma at its manufacturing facility in Lynnwood, WA.
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.
Autoimmune pulmonary alveolar proteinosis.

Local Bounti Announces Full Year 2023 Financial Results

Retrieved on:

Wednesday, March 27, 2024

USDA, Growth, Plant, Acceleration, Patent, Webcast, Research, Sale, Acquisition, Capital, Depreciation, Grab, Pacific Northwest, CEA, Modern Greek, Economics, Weather

"2023 was a defining year for Local Bounti, culminating in significantly expanded production capacity following the implementation of our now patented Stack & Flow Technology and optimization of our Georgia facility," stated Craig Hurlbert, CEO of Local Bounti.

Key Points:

"2023 was a defining year for Local Bounti, culminating in significantly expanded production capacity following the implementation of our now patented Stack & Flow Technology and optimization of our Georgia facility," stated Craig Hurlbert, CEO of Local Bounti.
With the facility now fully scaled, Local Bounti is focused on satisfying existing demand from retailers across the southeastern U.S.
As of December 31, 2023, Local Bounti had approximately 8.3 million shares outstanding, 6.2 million common shares under warrants outstanding, and approximately 0.7 million restricted stock units outstanding.
The Company will host a conference call with members of the Local Bounti executive management team.

Minister LeBlanc introduces legislation to further strengthen Canada's electoral process

Retrieved on:

Wednesday, March 20, 2024

Element, Public security, Democracy, Commissioner, Publishing, Artificial intelligence, Policy, Deepfake, Disclosure, Parliament, Elections Canada, Canada Elections Act, Privacy, Collection, CEA

The CEA is the fundamental legislative framework that regulates Canada's electoral process.

Key Points:

The CEA is the fundamental legislative framework that regulates Canada's electoral process.
It is independently administered by the Chief Electoral Officer and Elections Canada, with compliance and enforcement by the Commissioner of Canada Elections.
Recent experiences and lessons from the 2019 and 2021 general elections highlighted opportunities to further remove barriers to voting and encourage voter participation, protect personal information, and strengthen electoral safeguards.
To recognize the growing demand and lessons learned, the special ballot process would be improved from start to finish.

NM Holding, Nature’s Miracle and Lakeshore Acquisition II Corp. Announce Closing of Business Combination

Retrieved on:

Monday, March 11, 2024

Acquisition, Controlled-environment agriculture, CEA, Upland, California, LLP, LBBB

Upland, CA, March 11, 2024 (GLOBE NEWSWIRE) -- Nature’s Miracle Holding Inc. (“the Company”), Nature’s Miracle, Inc. (“Nature’s Miracle”), a growing Controlled Environment Agriculture (CEA) technology company, and Lakeshore Acquisition II Corp., a special purpose acquisition company (Nasdaq: LBBB) (“Lakeshore”), announced today the closing of their previously announced business combination (the “Transaction”).

Key Points:

Upland, CA, March 11, 2024 (GLOBE NEWSWIRE) -- Nature’s Miracle Holding Inc. (“the Company”), Nature’s Miracle, Inc. (“Nature’s Miracle”), a growing Controlled Environment Agriculture (CEA) technology company, and Lakeshore Acquisition II Corp., a special purpose acquisition company (Nasdaq: LBBB) (“Lakeshore”), announced today the closing of their previously announced business combination (the “Transaction”).
The Company will be led by Tie (James) Li, the Chairman of the Board and Chief Executive Officer, along with George Yutuc as the Chief Financial Officer.
Maxim Group LLC acted as the exclusive financial advisor to Lakeshore in connection with the Transaction.
Sichenzia Ross Ference Carmel LLP acted as legal counsel to Nature’s Miracle.